Q4 2025 Haleon PLC Earnings Call Transcript
Key Points
- Haleon PLC (HLN) reported a 220 basis points improvement in gross margin, driven by productivity programs and operational efficiencies.
- The company is confident in achieving organic sales growth of 3% to 5% for 2026, with plans to drive category growth and improve competitiveness.
- Haleon PLC (HLN) has made strategic organizational changes, including the appointment of a Chief Growth Officer and a Chief Transformation Officer, to unlock growth and agility.
- The Oral Health segment performed strongly, with high single-digit growth, supported by successful innovations like the Sensodyne clinical range.
- Emerging markets, particularly India and China, showed strong performance, with India achieving double-digit growth and China experiencing mid-single-digit growth.
- The company's organic sales growth of 3% in 2025 was below expectations, impacted by a softer cold and flu season and a slowdown in the US market.
- Haleon PLC (HLN) faced challenges in the US market, with lower inventory levels at key retailers like Walgreens and CVS affecting performance.
- The Digestive Health segment experienced a slowdown, particularly in the US, due to private label competition impacting brands like Nexium.
- Despite increasing A&P investment by 7.5%, the company faced negative volume growth, raising concerns about the effectiveness of marketing spend.
- The cold and flu category continues to be a challenge, with two consecutive years of lower-than-expected performance impacting overall growth.
Good morning. Thank you for attending today's Haleon's fiscal year 2025 results question-and-answer. My name is Sarah, and I'll be your moderator today. (Operator Instructions)
I would like to pass the conference over to our host, Jo Russell. Please go ahead.
Good morning, everyone, and welcome to Haleon's full year 2025 results Q&A conference call. I'm Jo Russell, Head of Investor Relations, and I'm joined this morning by Brian McNamara, our Chief Executive Officer; and Dawn Allen, our Chief Financial Officer.
Just to remind listeners on the call that in the discussions today, the company may make certain forward-looking statements, including those that refer to our estimates, plans and expectations. Please refer to this morning's announcement and the company's UK and SEC filings for more details, including factors that could lead to actual results to differ materially from those expressed or implied by such forward-looking statements.
We have posted today's presentation on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
